SCHEMBL3035804

SCHEMBL3035804

CCc1nc(Cl)c(C(=O)NCc2ccc(Cl)c(Oc3cccc4ccccc34)c2F)[nH]1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
MAPT P10636 1/20 0.39
PKM P14618 1/20 0.39
CYP2C19 P33261 1/20 0.39
SCN9A Q15858 2/20 0.37
ESRRA P11474 1/20 0.37
MAPK8 P45983 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CACNA1B Q00975 1/20 0.35
APBA1 Q02410 1/20 0.35
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
NPC1 O15118 2/20 0.33
KLKB1 P03952 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
CARM1 Q86X55 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13217563 0.90 PKM (0.40) CYP1A2CYP3A4CYP2D6MAPTPKM
SCHEMBL3035475 0.85 CYP1A2 (0.37) CYP1A2CYP3A4CYP2D6MAPTPKM
Trifluoroacetic Acid SCHEMBL3023115 0.85 CYP1A2 (0.37) CYP1A2CYP3A4CYP2D6MAPTPKM
SCHEMBL3028545 0.84 CYP1A2 (0.41) CYP1A2CYP3A4CYP2D6MAPTPKM
SCHEMBL13982210 0.79 PTGES (0.35) CYP3A4PTGES
SCHEMBL3027762 0.79 CYP3A4 (0.34) CYP3A4PTGESLMNA
SCHEMBL3022309 0.77 CYP3A4 (0.35) CYP3A4PKMSMN1; SMN2ALDH1A1PTGES
SCHEMBL3033004 0.77 CYP3A4 (0.35) CYP3A4PTGES
SCHEMBL3034619 0.77 CYP3A4 (0.48) CYP3A4CYP2C19PTGES
SCHEMBL13982111 0.76 PTGES (0.39) PTGES

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8304419-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2012-11-06 US disclosed
US-8304419-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2012-11-06 US disclosed
US-8304419-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2012-11-06 US disclosed
US-20100216746-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-26 US disclosed
US-20100216746-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-26 US disclosed
US-20100216746-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-26 US disclosed
WO-2008154271-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216746-A1 CHEMICAL COMPOUNDS SAMHD1, POLRMT, NUDT1 CYP1A2 301/4885CYP3A4 169/4885CYP2D6 288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.